4-Sep-2026
Ionis drops as Novartis posts late-stage trial setback for heart disease drug
Seeking Alpha News (Fri, 4-Sep 5:00 PM ET)
Wells Fargo Reaffirms Their Hold Rating on Amgen (AMGN)
TipRanks (Fri, 4-Sep 6:06 AM ET)
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
PRNewswire (Wed, 2-Sep 4:01 PM ET)
Amgen slapped with U.K. suspension of rare-disorder therapy Tavneos
Seeking Alpha News (Wed, 2-Sep 7:12 AM ET)
TipRanks (Mon, 31-Aug 9:30 AM ET)
4 stocks to watch on Monday: AMGN, LLY, ARM, and MSTR
Seeking Alpha News (Mon, 31-Aug 8:43 AM ET)
Amgen's Repatha cuts death risk by 20% in heart study
Seeking Alpha News (Mon, 31-Aug 5:07 AM ET)
AMGEN'S REPATHA REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
PRNewswire (Mon, 31-Aug 3:19 AM ET)
PRNewswire (Thu, 27-Aug 2:00 AM ET)
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
PRNewswire (Tue, 4-Aug 4:01 PM ET)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen trades on the NASDAQ stock market under the symbol AMGN.
As of September 4, 2026, AMGN stock price declined to $437.23 with 1,423,185 million shares trading.
AMGN has a beta of 0.13, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.00 to the broad based SPY ETF.
AMGN has a market cap of $236.38 billion. This is considered a Mega Cap stock.
Last quarter Amgen reported $10 billion in Revenue and $6.29 earnings per share. This beat revenue expectation by $629 million and exceeded earnings estimates by $.69.
In the last 3 years, AMGN traded as high as $447.03 and as low as $248.38.
The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, SCHD, VOO, QQQ, SPY.
AMGN has outperformed the market in the last year with a return of +59.6%, while the SPY ETF gained +19.8%. In the last 3 month period, AMGN beat the market returning +27.2%, while SPY returned +2.0%. However, in the most recent 2 weeks AMGN has underperformed the stock market by returning -0.5%, while SPY returned +0.6%.
AMGN support price is $437.51 and resistance is $450.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN shares will trade within this expected range on the day.